| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ERI.13.3 |
| P698 | PubMed publication ID | 23458770 |
| P2093 | author name string | Andres Beiras-Fernandez | |
| Florian Weis | |||
| Isabella Kanzler | |||
| P2860 | cites work | The changing epidemiology of Staphylococcus aureus? | Q22305657 |
| Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae | Q24656785 | ||
| A potential role for daptomycin in enterococcal infections: what is the evidence? | Q33845776 | ||
| Development of daptomycin for gram-positive infections | Q33920377 | ||
| Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens | Q33981048 | ||
| The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections | Q34330270 | ||
| Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry | Q34415953 | ||
| Daptomycin for the treatment of Gram-positive microorganisms in the critically-ill patient | Q42743421 | ||
| Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study | Q43209272 | ||
| Relapse of enterococcal prosthetic valve endocarditis with aortic root abscess following treatment with daptomycin in a patient not fit for surgery | Q43216748 | ||
| Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience | Q43258151 | ||
| Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis | Q43280982 | ||
| Multidrug-resistant gram-positive infections in patients with ventricular assist devices: the role of daptomycin | Q43283956 | ||
| High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis | Q43443557 | ||
| 10-year follow-up of patients with and without mediastinitis | Q44582185 | ||
| Risk factors for mediastinitis after cardiac surgery | Q44753619 | ||
| Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy. | Q44899027 | ||
| Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin | Q44991130 | ||
| Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin | Q45221988 | ||
| Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections | Q45230598 | ||
| Successful salvage therapy with daptomycin after linezolid and vancomycin failure in a liver transplant recipient with methicillin-resistant Staphylococcus aureus endocarditis. | Q45982608 | ||
| Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor | Q46061131 | ||
| Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis | Q46456918 | ||
| Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact | Q46494181 | ||
| Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. | Q46720912 | ||
| Rhabdomyolysis and acute renal failure in a patient treated with daptomycin | Q46892799 | ||
| Daptomycin in the treatment of bacteremia | Q46974833 | ||
| Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal. | Q47995896 | ||
| Algorithm for primary closure in sternal wound infection: a single institution 10-year experience | Q48024551 | ||
| Treatment of cardiovascular implantable electronic device infection with daptomycin | Q48756705 | ||
| Daptomycin for eradication of a systemic infection with a methicillin-resistant-Staphylococcus aureus in a biventricular assist device recipient. | Q50971807 | ||
| Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. | Q51154227 | ||
| Daptomycin: a novel agent for Gram-positive infections. | Q53852746 | ||
| Safety of daptomycin in patients receiving hemodialysis. | Q54559786 | ||
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| Clinical experience with daptomycin in Europe: the first 2.5 years | Q34681219 | ||
| Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects | Q34882125 | ||
| Prospective, open-label investigation of the pharmacokinetics of daptomycin during cardiopulmonary bypass surgery | Q35004882 | ||
| In vivo pharmacodynamic activity of daptomycin | Q35005549 | ||
| Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers | Q35091557 | ||
| Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus | Q35166213 | ||
| Treatment of gram-positive deep sternal wound infections in cardiac surgery--experiences with daptomycin. | Q35248216 | ||
| The rising problem of antimicrobial resistance in the intensive care unit | Q35595833 | ||
| Daptomycin | Q35637066 | ||
| High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis | Q36171512 | ||
| Daptomycin as supportive treatment option in patients developing mediastinitis after open cardiac surgery | Q36361545 | ||
| Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicity | Q36478933 | ||
| Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates | Q36972978 | ||
| Daptomycin: a review 4 years after first approval | Q36972980 | ||
| Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection | Q37217100 | ||
| Epidemiological and resistance issues in multidrug-resistant staphylococci and enterococci | Q37427879 | ||
| Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program | Q37509110 | ||
| Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients | Q37532488 | ||
| The clinical consequences of antimicrobial resistance | Q37589107 | ||
| Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis | Q37637758 | ||
| Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options | Q37781189 | ||
| Serious infections caused by methicillin-resistant Staphylococcus aureus | Q37781817 | ||
| Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature | Q37824612 | ||
| Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy | Q37956597 | ||
| Pharmacological agents for soft tissue and bone infected with MRSA: which agent and for how long? | Q37971167 | ||
| Management of infective endocarditis: challenges and perspectives | Q37982584 | ||
| Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports | Q38011845 | ||
| Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis | Q38499259 | ||
| Once-daily dosing in dogs optimizes daptomycin safety | Q39537062 | ||
| Indications for daptomycin use in endocarditis and pacemaker lead infection and outcomes in Leeds, UK. | Q39573063 | ||
| Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration | Q39587071 | ||
| In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis | Q39792691 | ||
| Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032) | Q39816283 | ||
| Daptomycin concentrations in valve tissue and vegetation in patients with bacterial endocarditis | Q42529523 | ||
| Daptomycin use in infants: report of two cases with peak and trough drug concentrations | Q42566536 | ||
| P433 | issue | 3 | |
| P921 | main subject | cardiac surgery | Q235007 |
| P304 | page(s) | 309-320 | |
| P577 | publication date | 2013-03-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Current use of daptomycin in cardiac surgery and postoperative intensive care | |
| P478 | volume | 11 |
Search more.